James N. Lowder

2.9k total citations
57 papers, 2.1k citations indexed

About

James N. Lowder is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, James N. Lowder has authored 57 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 17 papers in Oncology and 16 papers in Immunology. Recurrent topics in James N. Lowder's work include Monoclonal and Polyclonal Antibodies Research (14 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Epigenetics and DNA Methylation (9 papers). James N. Lowder is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Epigenetics and DNA Methylation (9 papers). James N. Lowder collaborates with scholars based in United States, United Kingdom and Austria. James N. Lowder's co-authors include Ronald Levy, TC Meeker, K Thielemans, DG Maloney, RA Miller, Roger A. Warnke, T C Meeker, Jeffrey Sklar, Michael L. Cleary and Stanford J. Stewart and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

James N. Lowder

54 papers receiving 2.0k citations

Peers

James N. Lowder
S. M. Steinberg United States
Isaac Ben‐Bassat Israel
Inmaculada de la Torre Spain
Michael Potter United Kingdom
Aaron S. Rosenberg United States
Gerald J. Elfenbein United States
Bethanie Wilkinson United States
Leona Holmberg United States
Martin Wilhelm Germany
Hilary Blacklock New Zealand
S. M. Steinberg United States
James N. Lowder
Citations per year, relative to James N. Lowder James N. Lowder (= 1×) peers S. M. Steinberg

Countries citing papers authored by James N. Lowder

Since Specialization
Citations

This map shows the geographic impact of James N. Lowder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James N. Lowder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James N. Lowder more than expected).

Fields of papers citing papers by James N. Lowder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James N. Lowder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James N. Lowder. The network helps show where James N. Lowder may publish in the future.

Co-authorship network of co-authors of James N. Lowder

This figure shows the co-authorship network connecting the top 25 collaborators of James N. Lowder. A scholar is included among the top collaborators of James N. Lowder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James N. Lowder. James N. Lowder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rockwood, Todd, Kyle Rudser, Leslie Rickey, et al.. (2025). Abbreviated version of the Bladder Health Scales for women's research. American Journal of Obstetrics and Gynecology. 234(2). e42–e53.
2.
3.
Fazio, Carolina, Alessia Covre, Ornella Cutaia, et al.. (2018). Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy. Frontiers in Pharmacology. 9. 1443–1443. 19 indexed citations
4.
5.
Roboz, Gail J., Hagop M. Kantarjian, Karen Yee, et al.. (2017). Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 124(2). 325–334. 49 indexed citations
6.
Issa, Jean‐Pierre J., Gail J. Roboz, David A. Rizzieri, et al.. (2015). Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. The Lancet Oncology. 16(9). 1099–1110. 210 indexed citations
7.
Dutcher, Janice P., Douglas J. Schwartzentruber, Howard L. Kaufman, et al.. (2014). High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. Journal for ImmunoTherapy of Cancer. 2(1). 26–26. 148 indexed citations
8.
Wong, Michael K., Howard L. Kaufman, Gregory A. Daniels, et al.. (2014). Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. Journal for ImmunoTherapy of Cancer. 2(1). 20–20. 4 indexed citations
9.
Sandborn, William J., Matthew Frankel, Daan W. Hommes, et al.. (2010). Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 59(11). 1485–1492. 58 indexed citations
10.
Baumgart, Daniel C., James N. Lowder, Stephan R. Targan, William J. Sandborn, & Matthew Frankel. (2009). Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Visilizumab (HuM291) in Crohn's Disease. The American Journal of Gastroenterology. 104(4). 868–876. 18 indexed citations
11.
Herrinton, Lisa J., et al.. (2008). Natural History of Severe Ulcerative Colitis in a Community-Based Health Plan. Clinical Gastroenterology and Hepatology. 6(9). 999–1003. 45 indexed citations
12.
Plevy, Scott E., Bruce Salzberg, Gert Van Assche, et al.. (2007). A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis. Gastroenterology. 133(5). 1414–1422. 90 indexed citations
13.
Carpenter, Paul A., James N. Lowder, Laura Johnston, et al.. (2005). A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 11(6). 465–471. 53 indexed citations
14.
15.
O’Gorman, Maurice R.G., Dietra D. Millard, James N. Lowder, & Ram Yogev. (1998). Lymphocyte subpopulations in healthy 1-3-day-old infants. Cytometry. 34(5). 235–241. 28 indexed citations
16.
Fiebig, Eberhard, et al.. (1997). Lymphocyte subset analysis on frozen whole blood. Cytometry. 29(4). 340–350. 29 indexed citations
17.
Porembka, David T., et al.. (1989). Etiology and management of doxorubicin cardiotoxicity. Critical Care Medicine. 17(6). 569–572. 9 indexed citations
18.
Wolff, Steven N., R H Herzig, Joseph W. Fay, et al.. (1989). High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group.. Journal of Clinical Oncology. 7(2). 245–249. 32 indexed citations
19.
Carroll, William L., et al.. (1986). Idiotype variant cell populations in patients with B cell lymphoma.. The Journal of Experimental Medicine. 164(5). 1566–1580. 46 indexed citations
20.
Lowder, James N.. (1982). Bacteremias and Fungemias in Oncologic Patients With Central Venous Catheters. Archives of Internal Medicine. 142(8). 1456–1456. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. M. Steinberg Breakdown of academic impact, for papers by Isaac Ben‐Bassat Breakdown of academic impact, for papers by Inmaculada de la Torre Breakdown of academic impact, for papers by Michael Potter Breakdown of academic impact, for papers by Aaron S. Rosenberg Breakdown of academic impact, for papers by Gerald J. Elfenbein Breakdown of academic impact, for papers by Bethanie Wilkinson Breakdown of academic impact, for papers by Leona Holmberg Breakdown of academic impact, for papers by Martin Wilhelm Breakdown of academic impact, for papers by Hilary Blacklock
Rankless by CCL
2026